Cargando…
A double-blind, randomized, placebo-controlled trial studying the effects of Saccharomyces boulardii on the gastrointestinal tolerability, safety, and pharmacokinetics of miglustat
BACKGROUND: Gastrointestinal (GI) disturbances such as diarrhea and flatulence are the most frequent adverse effects associated with miglustat therapy in type 1 Gaucher disease (GD1) and Niemann-Pick disease type C (NP-C), and the most common recorded reason for stopping treatment during clinical tr...
Autores principales: | Remenova, Tatiana, Morand, Olivier, Amato, Dominick, Chadha-Boreham, Harbajan, Tsurutani, Scott, Marquardt, Thorsten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501118/ https://www.ncbi.nlm.nih.gov/pubmed/26084276 http://dx.doi.org/10.1186/s13023-015-0297-7 |
Ejemplares similares
-
Improved Enzyme Replacement Therapy with Cipaglucosidase Alfa/Miglustat in Infantile Pompe Disease
por: Fiege, Lina, et al.
Publicado: (2023) -
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Saccharomyces boulardii in Infants and Children With Acute Diarrhea
por: Mourey, Florian, et al.
Publicado: (2020) -
Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports
por: Amato, Dominick, et al.
Publicado: (2018) -
Experience with Saccharomyces boulardii Probiotic in Oncohaematological Patients
por: Sulik-Tyszka, Beata, et al.
Publicado: (2017) -
Biocontainment strategies for in vivo applications of Saccharomyces boulardii
por: Hedin, Karl Alex, et al.
Publicado: (2023)